These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7621437)

  • 61. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
    Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
    Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.
    Neil GL; Kuentzel SL; McGovren JP
    Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
    Berezhnaya NM; Vinnichuk YD; Belova OB
    Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Photodynamic therapy in general surgery.
    Vietri F; Girolami M; Illuminati G; Belbusti M; Guglielmi R; Reddi E; Jori G
    G Chir; 1991; 12(6-7):367-70. PubMed ID: 1751324
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems.
    Johnson RK; Houchens DP; Gaston MR; Goldin A
    Cancer Chemother Rep; 1975; 59(4):697-705. PubMed ID: 1175164
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
    Ganapathi R; Grabowski D
    Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
    Ripamonti M; Pezzoni G; Pesenti E; Pastori A; Farao M; Bargiotti A; Suarato A; Spreafico F; Grandi M
    Br J Cancer; 1992 May; 65(5):703-7. PubMed ID: 1586598
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of malignant melanoma by high-peak-power 1064 nm irradiation followed by photodynamic therapy.
    Busetti A; Soncin M; Jori G; Kenney ME; Rodgers MA
    Photochem Photobiol; 1998 Sep; 68(3):377-81. PubMed ID: 9747592
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
    Yagi MJ; Chin SE; Scanlon KJ; Holland JF; Bekesi JG
    Biochem Pharmacol; 1985 Jul; 34(13):2347-54. PubMed ID: 4040366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines.
    Capranico G; De Isabella P; Castelli C; Supino R; Parmiani G; Zunino F
    Br J Cancer; 1989 May; 59(5):682-5. PubMed ID: 2567607
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.
    Formelli F; Cleris L; Carsana R
    Cancer Chemother Pharmacol; 1988; 21(4):329-36. PubMed ID: 3370742
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Photodynamic therapy of colorectal cancer using a new light source: from in vitro studies to a patient treatment.
    Kashtan H; Haddad R; Yossiphov Y; Bar-On S; Skornick Y
    Dis Colon Rectum; 1996 Apr; 39(4):379-83. PubMed ID: 8878495
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.
    Supino R; Mariani M; Prosperi E; Parmiani G
    Cancer Chemother Pharmacol; 1988; 21(3):251-4. PubMed ID: 3359560
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Photodynamic therapy of arteries. A novel approach for treatment of experimental intimal hyperplasia.
    Ortu P; LaMuraglia GM; Roberts WG; Flotte TJ; Hasan T
    Circulation; 1992 Mar; 85(3):1189-96. PubMed ID: 1537115
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
    Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Effectiveness of combined action of vitamins A, E and C and cyclophosphane or adriamycin on growth of transplanted tumors in mice].
    Mosienko VS; Khasanova LT; Sukolinskiĭ VN; Morozkina TS
    Eksp Onkol; 1990; 12(3):55-7. PubMed ID: 2344827
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
    Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
    Int J Cancer; 1993 Jan; 53(2):308-14. PubMed ID: 8425770
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.
    Formelli F; Supino R; Cleris L; Mariani M
    Br J Cancer; 1988 Apr; 57(4):343-7. PubMed ID: 3390370
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia.
    Burchenal JH; Kalaher K; O'Toole T; Chisholm J
    Cancer Res; 1977 Sep; 37(9):3455-7. PubMed ID: 884687
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of hexamethylhypericin and tetrabromohypericin to hypericin for their in vivo efficacy as PDT tools.
    Delaey E; Zupko I; Chen B; Derycke A; van Laar F; De Vos D; De Witte P
    Int J Oncol; 2003 Aug; 23(2):519-24. PubMed ID: 12851704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.